Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells

Japanese Journal of Cancer Research : Gann
Y HonmaK Umezawa

Abstract

The human chronic myelogenous leukemia cell line K562 expresses a structurally altered c-abl protein with tyrosine kinase activity. Erythroid differentiation of K562 cells was induced by tyrosine kinase inhibitors, but not by other kinase inhibitors. Treatment of K562 cells with 5'd(TACTGGCCGCTG-AAGGGC)3', complementary to the second exon (codons 2 to 7) of c-abl mRNA, inhibited cell growth and induced benzidine-positive cells in a dose-dependent manner. However, exposure to the sense oligomer did not induce erythroid differentiation of the cells. These results suggest that inhibition of abl tyrosine kinase activity is closely related to induction of erythroid differentiation of K562 cells. A multidrug-resistant subline (K562R) was induced to undergo erythroid differentiation by tyrosine kinase inhibitors such as genistein or herbimycin A as effectively as the parent K562 cells were. Therefore, tyrosine kinase inhibitors might be useful as cancer chemotherapeutic agents against some multidrug-resistant leukemias having abnormally high activity of oncogene tyrosine kinase(s).

References

Feb 1, 1979·International Journal of Cancer. Journal International Du Cancer·L C AnderssonC G Gahmberg
Dec 17, 1989·Biochimica Et Biophysica Acta·L Ramakrishnan, N Rosenberg
Sep 15, 1989·Biochemical and Biophysical Research Communications·Y UeharaS Mizuno
Nov 12, 1985·Biochimica Et Biophysica Acta·J B Konopka, O N Witte
Jan 1, 1983·Annual Review of Biochemistry·J M Bishop

❮ Previous
Next ❯

Citations

Oct 9, 1991·Biochemical Pharmacology·H FukazawaY Uehara
Jan 1, 1995·The Journal of Steroid Biochemistry and Molecular Biology·H AdlercreutzT Fotsis
May 30, 2001·Experimental Hematology·B N JahagirdarC M Verfaillie
Jul 1, 1997·Critical Reviews in Oncology/hematology·V Rizzoli, C Carlo-Stella
Jun 1, 1995·British Journal of Haematology·R CostelloD Maraninchi
Oct 1, 1995·Environmental Health Perspectives·H Adlercreutz
Jul 27, 2007·The Journal of Nutritional Biochemistry·Simone G J van BredaJoost H M van Delft
Oct 12, 2004·Leukemia Research·Antoine Ribadeau DumasMichel Arock
Apr 19, 2015·Biotechnology Advances·Franck MorceauMarc Diederich
Mar 24, 2004·The British Journal of Nutrition·Pamela J Magee, Ian R Rowland
Apr 24, 2003·Medicinal Research Reviews·Wenying RenLi Zhang
Jan 1, 1996·Journal of Cellular Biochemistry. Supplement·G J KelloffC C Sigman
Jan 1, 1996·Journal of Cellular Biochemistry. Supplement
Jan 1, 1994·Nutrition and Cancer·M J MessinaS Barnes
Jan 1, 1993·Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum·H AdlercreutzT Hase
Jan 1, 1996·La Revue de médecine interne·R CostelloJ Gabert
Nov 13, 1996·Biochimica Et Biophysica Acta·J Y LehtonenP K Kinnunen
Apr 7, 1995·Journal of Chromatography. B, Biomedical Applications·J G Supko, L R Phillips
Nov 1, 1992·Critical Reviews in Oncology/hematology·M A Lea

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.